Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsUpgradesPrice Target
Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.
Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.